-- Company Also Announces Participation in Upcoming Investor Conferences in
SAN DIEGO, Sept 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics,
Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment
of obesity and other central nervous system-related disorders, today
announced its active calendar of events for October 2008, which includes
six data presentations and one sponsored symposium at The Obesity Society
Annual Scientific Meeting, as well as upcoming corporate presentations at
noteworthy investor conferences.
The Obesity Society Annual Scientific Meeting, Phoenix Convention Center
Saturday, October 4
Title: "The Naltrexone-Bupropion Combination Reduces the Prevalence of the
Metabolic Syndrome and Improves Cardiometabolic Markers in At-Risk
Time: 5:00-7:00 p.m. MT
Sunday, October 5
Event Code: E1280
Title: "Reward and Obesity; Too Much of a Good Thing?"
Time: 6:15-7:45 a.m. MT
Location: Hyatt Regency Phoenix, Regency Ballroom A/B
Presenter: Ronald Landbloom, M.D.
Title: "Long Term Weight Loss from a Dose Optimization Study with
Zonisamide SR and Bupropion SR"
Time: 11:00-11:15 a.m. MT
Title: "Relative Bioavailability of Sustained-release (SR) versus
Immediate-release (IR) Naltrexone (NAL) Formulations in Healthy Obese
Volunteers: Implications for Improved Tolerability?"
Time: 5:30-7:30 p.m. MT
Monday, October 6
|SOURCE Orexigen Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved